FDA Approves Depomed's Proquin XR for Urinary Tract Infections

Depomed has received FDA approval for Proquin XR, a once-daily, extended-release formulation of ciprofloxacin HCl for the treatment of uncomplicated urinary tract infections (UTIs).

The market for ciprofloxacin is estimated at $1.5 billion worldwide in the U.S., with prescriptions for uncomplicated UTI's representing a significant portion of usage, Depomed said.